These findings position LSD1 as a key gatekeeper of MHC-I antigen presentation, offering a mechanistic basis for pairing LSD1 blockade with immune-checkpoint inhibitors to enhance outcomes in SCLC. The gene discussed is KDM1A; the disease is small cell lung carcinoma.